Niall M.B. Martin
4D Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, Cancer-related Molecular Pathways, Cancer therapeutics and mechanisms, RNA modifications and cancer
Most-Cited Works
- → Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy(2005)6,589 cited
- → Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM(2004)1,202 cited
- → High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs(2008)944 cited
- → Deubiquitylating enzymes and drug discovery: emerging opportunities(2017)911 cited
- → 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1(2008)573 cited
- → Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors(2012)511 cited
- → Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance(2021)340 cited
- → Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin(2008)332 cited
- → Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014(2013)204 cited
- → Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer(2005)189 cited